Yazar "Gencer Akçok, Emel Başak" için listeleme
-
Inhibition of PI3K-AKT-mTOR pathway and modulation of histone deacetylase enzymes reduce the growth of acute myeloid leukemia cells
Şansaçar, Merve; Sağır, Helin; Gencer Akçok, Emel Başak (HUMANA PRESS INC, 2023)One of the most widespread forms of blood cancer is known as acute myeloid leukemia (AML) which has an incidence of 80% with poor prognosis. Although there are different treatment methods for AML in clinic, the heterogeneity ... -
Pi3k-Akt-Mtor Yolağı Ve Histon Deasetilaz Enzimlerinin Hedeflenmesinin Akut Myeloid Lösemi Hücreleri Üzerine Antitümör Etkisinin Incelenmesi
Gencer Akçok, Emel Başak; Şansaçar, Merve; Karaca, Münevver; Okur, Tuğba (TÜBİTAK, 2022)Akut Miyeloid Lösemi (AML), periferik kan, kemik iliği, dalak ve karaciğerde blast adı verilen olgunlaşmamış miyeloid hücrelerin birikmesiyle karakterize edilen ve sonunda hematopoietik maligniteye yol açan bir hastalıktır. ... -
The therapeutic potential of targeting HDAC6 with Tubastatin A in TFK-1 and EGI-1 cholangiocarcinoma cells
Yenigül, Münevver; Gencer Akçok, Emel Başak (SİVAS CUMHURİYET ÜNİVERSİTESİ: Sivas Cumhuriyet University, 2021)Cholangiocarcinoma (CCA) is a highly aggressive and invasive malignancy with a poor diagnosis because of the resistance, relapse and limited therapy. Histone deacetylases (HDAC) are a class of enzyme that have important ... -
Tomatidine, a Steroidal Alkaloid, Synergizes with Cisplatin to Inhibit Cell Viability and Induce Cell Death Selectively on FLT3-ITD+ Acute Myeloid Leukemia Cells
Ayvaz, Havva Berre; Yenigül, Münevver; Gencer Akçok, Emel Başak (SPRINGER NATURE Link, 2024)Background: Acute Myeloid Leukemia (AML) is a hematological cancer that frequently presents with a range of side effects and drug resistance during anticancer drug treatment. The current study aims to achieve increased ...
